Kira Pharmaceuticals emerges from stealth with $46M and new CEO to lead complement therapy mission
Frederick Beddingfield left Sienna Biopharmaceuticals last December, a few months after the struggling biotech filed for bankruptcy. The former CEO was planning to take some time off, until he received a call from the University of Pennsylvania professor Wenchao Song.
Song was looking for someone to helm Kira Pharmaceuticals, a startup he co-founded to develop a “new generation” of complement-targeted therapies for immune-mediated diseases. The two got talking, one thing led to another, and “it just turned out to be a great fit,” Beddingfield said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.